ClinicalTrials.gg
CompletedNCT00461708Updated Oct 15, 2015Results posted

A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

A Phase 2 interventional study of Erlotinib and Gemcitabine in Pancreatic Cancer, sponsored by Hoffmann-La Roche. Completed at 29 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies testing erlotinib in Pancreatic Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. erlotinib · Pancreatic Neoplasms.

Enrollment
7th of 52
153 · median 32
Started
2007
with 7 others
Phase 2
27 of 53
none open now
Registered
18th of 53
by date
Lead sponsor
5 of 53
Hoffmann-La Roche

Among the 53 studies testing erlotinib in Pancreatic Neoplasms, this one is the 7th largest by enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2007, is one of 27 in phase 2, and was the 18th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

1 of the 53 studies testing erlotinib in Pancreatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About erlotinib

erlotinib: first FDA approval 2004 (TARCEVA), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing erlotinib in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This single arm study will evaluate the relationship between the skin toxicity of Tarceva in combination with gemcitabine, and survival, in patients with advanced and/or metastatic pancreatic cancer. All patients will receive gemcitabine 100mg/m2 i.v. weekly; Tarceva will be administered 100mg po per day. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • locally advanced and/or pancreatic cancer (stage III or IV);
  • performance Status of >=60%.

Exclusion criteria

Exclusion Criteria:

  • local(stage IA to IIB) pancreatic cancer;
  • \<=6 months since last chemotherapy;
  • previous systemic therapy for pancreatic cancer;
  • other primary tumor within last 5 years (except for adequately treated cancer in situ of cervix, or basal cell skin cancer);
  • cardiovascular disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Rash, Grade <2

    Participants with a rash graded less than (\<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m\^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.

    Drug: Erlotinib · Drug: Gemcitabine

  • Experimental
    Rash, Grade ≥2

    Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m\^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.

    Drug: Erlotinib · Drug: Gemcitabine

Interventions

  • 100 mg, PO, once per day

    Also known as: Tarceva

  • 1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Died During the Study

    Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.

  2. Overall Survival (OS) During the Study

    OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.

    Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.

Secondary outcomes

  1. Number of Participants Who Died at 6 Months

    Time frame: Enrollment through Cycle 6 (4-week cycles), up to 6 months.

  2. OS At 6 Months

    OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.

    Time frame: Enrollment through Cycle 6 (4-week cycles), up to 6 months.

  3. Number of Participants Who Died During the Study By Rash Grade

    Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.

  4. OS By Rash Grade

    OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.

    Time frame: Enrollment through Cycle 24 (4-week cycles), up to 24 months.

  5. Number of Participants With Disease Progression or Death

    Progression-free survival (PFS) was defined as the time from the date of enrollment to the date of document disease progression or death due to any cause. As per Response Evaluation Criteria in Solid Tumors (RECIST) V 1.0, progressive disease (PD) was defined for target lesions (TLs) as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded since the start of treatment, and for non-target lesions (NTLs) as unequivocal progression of NTLs. Participants whose last recorded status was not PD or death were censored.

    Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.

  6. PFS

    The time, in months, from enrollment to PFS event. Participants whose last recorded status was not progression or death were censored. PFS was estimated using Kaplan-Meier methodology.

    Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months

  7. Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST

    As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline (BL) SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.

    Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.

  8. Percentage of Participants With Disease Control According to RECIST

    Disease control was defined as BOR of CR, PR, or stable disease (SD). As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.

    Time frame: Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.

07

Results

Posted Oct 15, 2015

Participant flow

Participant flow — Overall Study
MilestoneErlotinib, Gemcitabine: Rash Grade Less Than (<) 2Erlotinib, Gemcitabine: Rash Grade Greater Than/Equal to (≥) 2
Started11538
Completed00
Not completed11538
Withdrew: Adverse event177
Withdrew: Lack of efficacy6820
Withdrew: Physician decision104
Withdrew: Withdrawal by subject82
Withdrew: Other44
Withdrew: Death81

Outcome measures

PrimaryNumber of Participants Who Died During the Study
Time frame:
Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Reported as:
Number · participants
Number of Participants Who Died During the Study
participantsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Number of Participants Who Died During the Study10227
PrimaryOverall Survival (OS) During the Study

OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.

Time frame:
Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Reported as:
Median · months
Overall Survival (OS) During the Study
monthsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Overall Survival (OS) During the Study4.468 (3.618 to 5.318)10.546 (9.679 to 11.414)
SecondaryNumber of Participants Who Died at 6 Months
Time frame:
Enrollment through Cycle 6 (4-week cycles), up to 6 months.
Reported as:
Number · participants
Number of Participants Who Died at 6 Months
participantsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Number of Participants Who Died at 6 Months698
SecondaryOS At 6 Months

OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.

Time frame:
Enrollment through Cycle 6 (4-week cycles), up to 6 months.
Reported as:
Median · months
OS At 6 Months
monthsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
OS At 6 Months4.468 (3.618 to 5.318)NA (NA to NA)
SecondaryNumber of Participants Who Died During the Study By Rash Grade
Time frame:
Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Reported as:
Number · participants
Number of Participants Who Died During the Study By Rash Grade
participantsErlotinib, Gemcitabine: Rash Grade 0Erlotinib, Gemcitabine: Rash Grade 1Erlotinib, Gemcitabine: Rash Grade ≥ 2
Number of Participants Who Died During the Study By Rash Grade653727
SecondaryOS By Rash Grade

OS was defined as the time, in months, from the date of enrollment to the date of death due to any cause. Participants whose last recorded status was not death were censored. OS was estimated using Kaplan-Meier methodology.

Time frame:
Enrollment through Cycle 24 (4-week cycles), up to 24 months.
Reported as:
Median · months
OS By Rash Grade
monthsErlotinib, Gemcitabine: Rash Grade 0Erlotinib, Gemcitabine: Rash Grade 1Erlotinib, Gemcitabine: Rash Grade ≥ 2
OS By Rash Grade3.318 (2.446 to 4.191)6.571 (5.139 to 8.003)10.546 (9.679 to 11.414)
SecondaryNumber of Participants With Disease Progression or Death

Progression-free survival (PFS) was defined as the time from the date of enrollment to the date of document disease progression or death due to any cause. As per Response Evaluation Criteria in Solid Tumors (RECIST) V 1.0, progressive disease (PD) was defined for target lesions (TLs) as at least a 20 percent (%) increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded since the start of treatment, and for non-target lesions (NTLs) as unequivocal progression of NTLs. Participants whose last recorded status was not PD or death were censored.

Time frame:
Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.
Reported as:
Number · participants
Number of Participants With Disease Progression or Death
participantsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Number of Participants With Disease Progression or Death11033
SecondaryPFS

The time, in months, from enrollment to PFS event. Participants whose last recorded status was not progression or death were censored. PFS was estimated using Kaplan-Meier methodology.

Time frame:
Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months
Reported as:
Median · months
PFS
monthsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
PFS2.497 (2.130 to 2.864)6.439 (4.919 to 7.960)
SecondaryPercentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST

As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline (BL) SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.

Time frame:
Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST
percentage of participantsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to RECIST7.021.1
Statistical analysis
  • Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2 · Chi-squared · p = <0.05
SecondaryPercentage of Participants With Disease Control According to RECIST

Disease control was defined as BOR of CR, PR, or stable disease (SD). As per RECIST V 1.0: for TLs, a CR was defined as the disappearance of all TLs; and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the BL SLD; SD was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Participants for whom no assessment of response was available and who had finalized the study due to disease progression or tumor-related death, disease progression was considered the BOR.

Time frame:
Enrollment, every 2 treatment cycles (4-week cycles) until disease progression, death, or end of study, for up to 24 months.
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control According to RECIST
percentage of participantsErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Percentage of Participants With Disease Control According to RECIST42.684.2
Statistical analysis
  • Erlotinib, Gemcitabine: Rash Grade < 2 vs Erlotinib, Gemcitabine: Rash Grade ≥ 2 · Chi-squared · p = <0.05

Adverse events

Collected over Adverse events (AEs) were recorded at every study visit for up to a maximum of 24 treatment cycles.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Erlotinib, Gemcitabine: Rash Grade < 2—58/115 (50.4%)115/115 (100%)
Erlotinib, Gemcitabine: Rash Grade ≥ 2—14/38 (36.8%)38/38 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
Obstruction, GIGastrointestinal disorders11/1152/38
Lung (pneumonia)Infections and infestations3/1153/38
FeverGeneral disorders4/1152/38
BloodInfections and infestations4/1152/38
CNS Cerebrovascular ischemiaNervous system disorders1/1152/38
Abdomen nosGastrointestinal disorders5/1150/38
FatigueGeneral disorders4/1151/38
Haemorrhage, GIGastrointestinal disorders3/1151/38
Respiratory failureRespiratory, thoracic and mediastinal disorders1/1151/38
Left ventricular dysfunctionCardiac disorders0/1151/38
Most frequent other events
Showing 10 of 150
Most frequent other events
EventErlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2
FatigueGeneral disorders89/11531/38
Abdomen nosMusculoskeletal and connective tissue disorders78/11519/38
AnorexiaMetabolism and nutrition disorders62/11511/38
DiarrheaGastrointestinal disorders55/11515/38
NeutropeniaBlood and lymphatic system disorders20/11516/38
NauseaGastrointestinal disorders43/11512/38
ConstipationGastrointestinal disorders38/11512/38
VomitingGastrointestinal disorders34/1158/38
FeverGeneral disorders18/11511/38
AnaemiaBlood and lymphatic system disorders32/11511/38

Baseline characteristics

Intent-to-treat (ITT) population: all participants included in the study.

Age, Continuous
Age, Continuous(years)Erlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2Total
Mean63.6 ± 9.962.0 ± 10.663.2 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Erlotinib, Gemcitabine: Rash Grade < 2Erlotinib, Gemcitabine: Rash Grade ≥ 2Total
Female611071
Male542882
08

Study locations

29 sites
  • Alcoy, Alicante 03804, Spain
  • Elche, Alicante 03203, Spain
  • Manresa, Barcelona 08243, Spain
  • Sabadell, Barcelona, Barcelona 08208, Spain
  • Santander, Cantabria 39008, Spain
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • La Coruna, La Coruña 15006, Spain
  • Alcorcon, Madrid 28922, Spain
  • Sagunto, Valencia 46520, Spain
  • Barcelona, 08227, Spain
  • Barcelona, 08906, Spain
  • Barcelona, 08907, Spain
  • Barcelona, 08916, Spain
  • Cordoba, 14004, Spain
  • Girona, 17007, Spain
  • Granada, 18014, Spain
  • Guadalajara, 19002, Spain
  • Jaen, 23007, Spain
  • Lerida, 25198, Spain
  • Lugo, 27004, Spain
  • Madrid, 28040, Spain
  • Madrid, 28041, Spain
  • Murcia, 30008, Spain
  • Murcia, 30120, Spain
  • Navarra, 31008, Spain
  • Pontevedra, 36002, Spain
  • Sevilla, 41013, Spain
  • Valencia, 41014, Spain
  • Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2007
First posted
Apr 18, 2007
Start
May 2007
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Oct 15, 2015
Last update
Oct 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00461708
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 18, 2007
Start date
May 2007
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Oct 15, 2015
Last update
Oct 15, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erlotinib · Gemcitabine

Start the discussion